Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a lupus drug protect kidneys in IgA disease? new trial aims to find out.

NCT ID NCT06350630

Disease control Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether hydroxychloroquine, a drug already used for lupus, can slow kidney function decline in people with IgA nephropathy (Berger's disease). About 334 adults with biopsy-confirmed IgA nephropathy and high protein in their urine will receive either hydroxychloroquine or a placebo for up to 2 years. The goal is to see if the drug helps preserve kidney function and reduce protein leakage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 334 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Social security affiliation * Signed informed consent * With biopsy proven IgA nephropathy (any vintage) * With at least one Oxford lesion (M, E, S, T, C) on last available kidney biopsy - With urine albumin/creatinine \> 300mg/g, * under maximal tolerated labeled dose of renin-angiotensin-aldosterone system (RAAS) inhibitors for at least 3 months * Sodium-Glucose Transport Protein 2 (SGLT-2) inhibitors initiated at least 1 month before inclusion visit * Only patients treated with SGLT2i and RAAS dual therapy before inclusion * With estimate GFR above 15 mL/min/1,73m² (Chronic Kidney Disease - EPIdemiology collaboration CKD-EPI formula) * Woman in childbearing with a highly effective method of contraception * Agreement of woman in childbearing potential (WOCBP) to perform a urine pregnancy test every month until three months after the end of study treatment * Agreement of fertile male with WOCBP partner to use a condom for the duration of the study treatment up to 3 months after treatment the end of study treatment. Exclusion Criteria: * Secondary IgA nephropathy (Henoch Schonlein purpura, cirrhosis, inflammatory bowel disease) * Corticosteroid or immunosuppressive therapies in the past year before screening * Contra-indication to hydroxychloroquine (retinopathy, maculopathy, history of intolerance to hydroxychloroquine…) * Uncontrolled hypertension (systolic blood pression\> 160 mmHg and/or diastolic blood pression \>110 mmHg ) * Long QT interval and/or QT prolonging medicines * Pregnancy or lactation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IgA nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IgA nephropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HM Hôpital de la Conception

    RECRUITING

    Marseille, 13385, France

  • APHP Hôpital Bichat

    RECRUITING

    Paris, 75018, France

  • APHP Hôpital de Tenon

    RECRUITING

    Paris, 75020, France

  • CHU Gabriel Montpied

    RECRUITING

    Clermont-Ferrand, 63000, France

  • CHU Lyon Sud

    RECRUITING

    Pierre-Bénite, 69495, France

  • CHU de Saint-Etienne

    RECRUITING

    Saint-Etienne, 42055, France

  • Hospices Civils de Lyon

    RECRUITING

    Lyon, 69437, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.